U 46619: Potent Thromboxane Receptor Agonist for Platelet and Renal Studies

Executive Summary: U 46619 (11,9 epoxymethano-prostaglandin H2) is a synthetic agonist that selectively activates the thromboxane (TP) receptor, a G-protein coupled receptor central to platelet function and vascular tone regulation. At nanomolar concentrations, U 46619 triggers platelet shape change and myosin light chain phosphorylation (MLCP), while higher concentrations induce platelet aggregation and serotonin release (APExBIO, product page). In vivo, it causes renal cortical vasoconstriction and increases blood pressure in hypertensive rat models by activating ETA and ETB receptors (Huang et al., 2026). U 46619 is supplied by APExBIO as a 10 mg/mL methyl acetate solution and is highly soluble in DMSO, ethanol, and DMF. It is intended strictly for research use and not for diagnostic or therapeutic applications.

Biological Rationale

The prostaglandin signaling pathway is integral to cardiovascular physiology, mediating processes such as hemostasis, vascular tone, and inflammation. Thromboxane A2 (TxA2) and prostaglandin H2 (PGH2) are potent eicosanoids acting via the TP receptor, a G-protein coupled receptor expressed in platelets and vascular smooth muscle. U 46619, a synthetic stable analogue of PGH2, is designed to selectively mimic TxA2/PGH2 activity, providing a consistent tool for dissecting TP-mediated pathways (APExBIO).

In research, U 46619 is widely employed to induce platelet aggregation, enabling detailed study of platelet activation cascades and testing of anti-platelet compounds. Its effects on renal vasculature and blood pressure also make it valuable for modeling hypertension and ischemia-reperfusion injury mechanisms (Huang et al., 2026).

Mechanism of Action of U 46619

U 46619 acts as a highly selective agonist of the thromboxane (TP) receptor, which is coupled to G-proteins (mainly Gq and G12/13). Upon binding, it triggers phospholipase C activation, leading to inositol trisphosphate (IP3) generation and intracellular calcium release. This cascade initiates platelet shape change and myosin light chain phosphorylation (MLCP) at EC50 values of 0.035 μM and 0.057 μM, respectively (APExBIO).

At higher concentrations, U 46619 further promotes serotonin release (EC50 = 0.536 μM), fibrinogen receptor binding (EC50 = 0.53 μM), and robust platelet aggregation (EC50 = 1.31 μM). In vivo, it induces renal cortical vasoconstriction and medullary vasodilation in rats, reflecting complex vascular responses to TP receptor activation (Huang et al., 2026).

Evidence & Benchmarks

• U 46619 induces human platelet shape change with an EC50 of 0.035 μM under physiological buffer conditions (APExBIO).
• Myosin light chain phosphorylation (MLCP) in platelets occurs at an EC50 of 0.057 μM after U 46619 stimulation in vitro (APExBIO).
• Serotonin release from platelets requires higher U 46619 concentrations (EC50 = 0.536 μM), indicating stepwise activation of secretory pathways (APExBIO).
• Platelet aggregation is robustly induced at EC50 = 1.31 μM, providing a reproducible benchmark for anti-platelet drug testing (APExBIO).
• In rodent models, intracerebroventricular U 46619 administration causes a dose-dependent increase in blood pressure without significant heart rate change, confirming its vasoactive properties (Huang et al., 2026).
• U 46619-mediated TP receptor activation has been used to model renal ischemia-reperfusion injury and to evaluate protective interventions, such as rhBNP, in preclinical studies (Huang et al., 2026).

For further contrast and context, see our prostaglandin E2 receptor signaling overview, which details EP receptor pathways distinct from TP-mediated effects; this article focuses on the TP receptor and platelet/renal endpoints.

Applications, Limits & Misconceptions

U 46619 is a staple in cardiovascular and platelet biology research:

• Platelet Function Studies: Used to induce aggregation in washed human or animal platelets under controlled conditions.
• Receptor Pharmacology: Helps characterize TP receptor antagonists and downstream pathway modulators.
• Renal and Vascular Models: Models renal ischemia, vasoconstriction, and hypertension, especially in preclinical rat studies (Huang et al., 2026).
• Drug Screening: Serves as a positive control for evaluating anti-platelet or anti-hypertensive candidate compounds.

Common Pitfalls or Misconceptions

• U 46619 is not a direct substitute for endogenous TxA2 or PGH2 in all cell types; receptor expression and coupling may differ.
• It is not suitable for diagnostic or therapeutic use in humans (per APExBIO guidelines).
• Effects in non-platelet tissues (e.g., neurons, immune cells) are less well characterized and may not be representative.
• Overinterpretation of results is possible in species or models with atypical TP receptor pharmacology.

For more on the boundaries of prostaglandin research tools, see our thromboxane synthesis pathway explainer (this article extends the focus to exogenous agonist utility).

Workflow Integration & Parameters

Solubility & Handling: U 46619 is supplied by APExBIO as a 10 mg/mL solution in methyl acetate (SKU: B6890). It is soluble at ≥100 mg/mL in DMSO, ethanol, and DMF, and at ≥2 mg/mL in PBS (pH 7.2). For optimal dissolution, warming to 37°C or using an ultrasonic bath is recommended. For short-term storage, maintain solutions at -20°C (APExBIO).

Experimental Design: Typical working concentrations range from 0.03 μM (for shape change) up to 2 μM (for full platelet aggregation). Control experiments should include vehicle and/or receptor antagonist arms. All work should be conducted under institutional guidelines for research reagents.

For workflow protocols contrasting U 46619 and other eicosanoid agonists, consult our platelet activation assay standards (this article provides updated EC50 values and handling tips for U 46619).

Conclusion & Outlook

U 46619 remains a gold-standard tool for investigating TP receptor biology and platelet activation, with clearly defined pharmacological benchmarks and robust reproducibility. Its utility in renal ischemia and hypertension modeling continues to expand, supported by preclinical evidence and precise solubility/handling parameters (Huang et al., 2026). As research advances, integrating U 46619 with genetic and proteomic methods will further clarify TP receptor signaling in health and disease.

For ordering and technical details, refer to the U 46619 product page (APExBIO B6890).